Cognition Therapeutics reports results from Phase 2 COG2201 trial

Cognition Therapeutics (CGTX) reported topline results from the Phase 2 COG2201 ‘MAGNIFY’ trial of zervimesine in adults with geographic atrophy secondary to dry age-related macular degeneration. The results show zervimesine-treated participants had 28.6% slower GA lesion growth on average and at 18 months, their lesions were 28.2% smaller compared to placebo. The MAGNIFY study was concluded, after approximately 100 of the planned 246 participants were enrolled. GA is characterized by the formation of lesions composed of dead retinal cells and undegraded waste proteins, creating blind spots in central vision. The change in GA lesions was measured using two methods: growth rate and size. Growth rate: in MAGNIFY, a slope analysis showed that the trajectory of GA had slowed by 28.6% in participants treated with zervimesine. Size: at 18 months, the mean lesion size for zervimesine-treated participants was 28.2% smaller than placebo-treated.